Mylan (MYL) PT Raised to $44 at BofA/Merrill Lynch Following Generic Estrace Cream Approval
Tweet Send to a Friend
BofA/Merrill Lynch raised its price target on Mylan (NASDAQ: MYL) to $44.00 (from $41.00) while maintaining a Neutral rating following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
